Complete Neutralization of Live COVID-19 Virus Via Revolutionary Patented Vaccine Technology
PULLMAN, WA and SALT LAKE CITY, UT Dec. 4, 2020 – Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised. IVT will manage and optimize vaccine manufacturing and distribution in partnership with global leaders in peptide manufacturing.
“Our most recent preclinical studies show complete biological and physical neutralization of live SARS-CoV-2 virus in vitro, and we have very encouraging results with high antibody titers, a durable T-Cell response and strong binding to targets on the virus S-Protein.”- Dr. Colin Collins, Chief Scientific Officer and Co-Founder HTI.
“The leap from traditional vaccine production to our highly scalable manufacturing technology is a breakthrough similar to the transition from vacuum tubes to silicon microprocessor chips.” – Robert Bogden, CEO and Co-Founder of HTI.
Numerous advantages are generated through the technology and joint collaboration:
Manufacturing Safety: the self-assembling vaccine is made from simple peptides and does not rely on chickens, bacteria or mammalian cells for production.
Manufacturing Throughput: a BILLION doses can be made in just weeks’ time (hundreds of times faster than other vaccines currently in clinical trials).
Supply Logistics: the vaccine can be shipped and stockpiled as a dry powder without special cold- chain considerations (i.e. many mRNA vaccines need -112F storage and have a short shelf life).
Safety: the vaccine specifically targets the virus S-Protein, is non-GMO, and aluminum free. It is well tolerated and safe, thus giving piece of mind to the public. It is not based on monkey adenoviruses or Virus Like Particles or GMO recombinant technologies which may prove unsafe.
Efficacy: the vaccine stimulates antibody production from the same areas of the corona virus upon which many monoclonal antibody therapies are based.
Versatility: as new viral strains emerge that are resistant to current vaccines, the self-assembling vaccine can be quickly modified to target the mutated virus.
For more information contact:
Robert Bogden
CEO and Co-Founder
Hexamer Therapeutics Inc.
Email: bogden@hexthera.com
Web: hexamertherapeutics.com
Dr. Colin Collins
CSO and Co-Founder
Hexamer Therapeutics Inc.
Email: ccollins@hexthera.com